Astellas at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Astellas brings 3 presentations to ENA 2026 in Barcelona. Its posters centre on KRAS-targeted drugs, both inhibitors and degraders, in KRAS-mutant preclinical models. They cover ASP2453, a KRAS G12C inhibitor, the KRAS-G12D degrader setidegrasib (ASP3082) and its combination potential, and ASP5834, a pan-KRAS degrader.

Organization	ENA 2026 Attendance
Astellas Tokyo, Japan
astellas.com Large pharma Pharmaceutical company with marketed cancer drugs and a pipeline including KRAS inhibitors and degraders.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents ASP2453, a novel KRAS G12C inhibitor, shows potent anti-tumor activity in various KRAS G12C-mutated preclinical models including genetically engineered mouse model Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Characterization of KRAS-G12D ubiquitination and degradation by setidegrasib (ASP3082) and its combination potential in preclinical models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs ASP5834, a novel pan-KRAS degrader, shows potent anti-tumor activity in KRAS mutant cancer models Drug design

Organization

ENA 2026 Attendance

Astellas

Tokyo, Japan

astellas.com

Large pharma

Pharmaceutical company with marketed cancer drugs and a pipeline including KRAS inhibitors and degraders.

Poster

Thu Nov 19
9:30–10am
1–3pm
4:30–5pm

Part of Poster session: Molecular Targeted Agents

ASP2453, a novel KRAS G12C inhibitor, shows potent anti-tumor activity in various KRAS G12C-mutated preclinical models including genetically engineered mouse model

Targeted agents